Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.

Authors

Shannon Puhalla

Magee Womens Hospital, Pittsburgh, PA

Shannon Puhalla , Sharon Wilks , Adam Brufsky , Joyce O'Shaughnessy , Lee Steven Schwartzberg , Erhan Berrak , James Song , David Cox , Linda T. Vahdat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 Breast Cancer Symposium

bookmark_border

Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from 2 phase 2, multicenter, single-arm studies.

First Author: Stefan Gluck

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies.

First Author: Stefan Gluck

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

First Author: Ines Maria Vaz Duarte Luis

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).

First Author: Ahmad Awada